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Abstract 
   Infections transmitted in blood transfusions are the most significant concern 
associated with blood donation. The purpose of this study was to establish the current 
prevalence of hepatitis viruses (B and C), HIV and T.pallidium among blood donors at 
National Blood Transfusion and Research Center (NBTRC) Hodeida Branch, Hodeida 
city, Yemen. Serological markers of HBV, HCV, HIV 1, 2, T.pallidium antibodies were 
studied in 25446 (males) using commercially available kits, over a period of 3 years 
from January 2016 to April 2018 at National Blood Transfusion and Research Center 
(NBTRC) Hodeida Branch , Hodeida city, Yemen. Also, the prevalence of confirmed-
positive test results of these infections was evaluated among different ages. The sero-
prevalence of HBV and HCV, HIV, T.pallidium infections based on confirmation tests, 
were 0.74%, 0.19%, 0.38% and 0.18% respectively. The prevalence of HBV was 
significantly higher in age groups 37-46 years and 47-56 years with significant 
associated OR equal to 2.3 (p<0.001) and OR=2.7 (p=0.02) respectively. The 
prevalence of HCV was significantly higher in age groups 47-56 years with significant 
associated OR equal to 6.5 (p=0.003).  The prevalence of T.pallidium was significantly 
higher in age group 37-46 years with significant associated OR equal to 3.6 (p<0.001). 
In conclusion: this study highlights the prevalence of HBV, HCV, HIV, and 
T.pallidium among different male ages. The prevalence varies from one age group to 
another, being the lowest among younger and very older age groups. Therefore, 
extensive recruitment of young donors should help ensure a long-term increase in the 
blood supply without jeopardizing safety. 
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Introduction  
Blood transfusion is one of the most important tools in modern medical therapy, and 
saving patients is its aim. If the safe blood supply is not considered, it can be life-
threatening. However, the blood has its potential risks causing serious side effects in 
the recipients. It is known that bacteria, viruses and parasites can be transmitted 
through blood transfusions 
1,2
. Choosing healthy donors with low risk of blood 
contamination is one of concerns around the world. The World Health 
  
Organization (WHO) recommends that all donated blood be tested for transfusion 
transmissible infections. These include HIV, Hepatitis B, Hepatitis C, Treponema 
pallidum (syphilis) and, where relevant, other infections that pose a risk to the safety of 
the blood supply, such as Trypanosoma cruzi (Chagas disease) and Plasmodium species 
(malaria)
3
. 
 According to the WHO, 25 countries are not able to screen all donated blood for one or 
more of: HIV; Hepatitis B; Hepatitis C; or syphilis.  One of the main reasons for this is 
because testing kits are not always available.  However the prevalence of transfusion-
transmitted infections is much higher in low income countries compared to middle and 
high income countries 
4,5
.  HBV, HCV, HIV and Treponema pallidium (syphilis) 
infections are important causes of morbidity and mortality worldwide and pose 
problems in the safety of blood transfusion.  Because of the shared modes of 
transmission, HBV/HCV/HIV/T.pallidium co-infection is not uncommon in highly 
endemic areas and among subjects with a high-risk of parenteral transmission. 
Prolonged vascular exposure and multiple blood transfusions increase the risk of 
acquiring these blood-borne infections in endemic areas as Yemen. According to the 
Yemeni National Infectious Viral Hepatitis Control Programme, Yemen was 
recognized as HBV-endemic area
6
. In 1998 the WHO recommended the entrance of 
hepatitis B vaccine in the national immunization programmes of Yemen
7
, particularly 
among neonates, where vertical transmission is common, regardless of the HBsAg  
prevalence. The incidence of acute HBV has declined dramatically during the past 
decade after the vaccination programme, especially among young individuals, 
although, it still may take several decades until the effect of vaccination will be 
translated into reduced transmission and morbidity in general. The purpose of this study 
was to establish the current prevalence of hepatitis viruses (B and C), HIV and 
T.pallidium among blood donors at National Blood Transfusion and Research Center 
(NBTRC) Hodeida Branch, Hodeida city, Yemen. 
Subjects and Methods 
This was a retrospective study. The study was depending on data collection from the 
records of National Blood Transfusion & Research Center (NBTRC) Hodeidah Branch 
,Yemen. The study data included data of  three Years from 1st of January 2016 to 30th 
of April 2018. A total of 25446 of blood donors were included in this study. They were 
the blood donors whom came to NBTRC for blood donation during 3 years . The 
donor's ages ranged from 17–>56 years with healthy normal weight (not less than 50 
kg) . The data collected  included:  gender, address, blood pressure, Weight, blood 
group, Hb level, the date of donation, the donation number, and the screening test 
  
results for HBV, HCV, HIV and Syphilis.  Blood donation in Yemen is depending on 
male donors and it is rare for female to be blood donors. Also blood donation is semi-
voluntary by friends and relatives of patients but voluntary donation is not the role.  
Blood Testing:  
The blood donors sera were tested by rapid immunochromatographic assay (RICA) kits 
and confirmed by ELISA test (ABON )for diagnosis of Hepatitis B surface Antigen 
(HBsAg ), antibodies to HCV, antibodies to HIV, and antibodies (IgG and IgM) for 
Treponema Pallidum (TP).  
Inclusion Criteria of blood donors:  
Potential donors were accept for donation if they are clinically healthy individuals 
between 18-60 years of age, with body weight of above 45Kgs, Hemoglobin more than 
12.5gm/dl and no significant medical or surgical history.   
 Exclusion Criteria  
Potential donors were excluded if they were below 17 years old, weighed less than 45 
kg, had anemia and a history of jaundice within the past six months, engaged in high-
risk behavior (i.e., unsafe intercourse, drug use etc), or donated blood within the past 
three months . 
Statistical Analysis 
To relate age as possible risk factor for HBV, HCV, HIV and T.pallidium  infections, 
the data were examined in a case-control study format. With confirmed positive tests of 
HBV, HCV, HIV and T.pallidium  were matched up with those who were HBV, HCV, 
HIV or T.pallidium   negative.  The chi square was used to see the association Odds 
ratios (OR) and their 95% confidence intervals (CI). Values (OR, CI, χ2) were 
estimated using 2x2 tables to identify possible odds ratio on occurrence of HBV, HCV, 
HIV or T.pallidium and their significance. The result at p-value 0.05 was considered as 
statistically significant.  
Ethical Consideration 
Ethical clearance for the study was taken from the Faculty of Medicine and Health 
Sciences Research Review Committee.  
Results 
A total number of 25446 blood donors were included in this study. The prevalence of 
HBV, HCV, HIV, and T.pallidium were 0.74%, 0.19%, 0.38%, and 0.18%, respectively 
with total prevalence of tested infectious agents equal to 1.52% (table 1). When age 
groups of blood donors were considered, there was significant increase in HBV rate in 
age group 47-56 years (1.94% with associated OR equal to 2.7; 95% CI=1.1-6.6, χ 2 
=5.1, and p=0.02), followed by age group 37-46 years (1.44%, OR=2.3; 95% CI=1.6-
3.1, χ2=5.1, p=0.02. However, lower rate of HBV was found in younger age groups 
(table 2). Also, a high prevalence of HCV was in  age group 47-56 years (1.2%) with 
  
associated OR equal to 6.5; 95% CI =1.9-20.9, χ 2 =12.8,and p=0.003. However, low 
prevalence rate of HCV was found in other age groups and 0% was found in age group 
>56 years (table 3). On other hand, there was no significant variation of the prevalence 
of HIV among the different age groups of the blood donors; and zero prevalence of 
HIV was found in older age groups (47-56 years and >56 years) (table 4). A higher  
prevalence of  T.pallidium was found in  age group 37-46 years (0.49%) with 
associated OR equal to 3.6 (95% CI=1.9-6.8,  χ 2 =19.4, p<0.001). However, low rate 
of T.pallidium was found in younger age groups and 0% was found in age group >56 
years (table 5). 
Discussion 
The prevalence of HBV (0.74%) and HCV (0.19%) in the current study are lower than 
previously reported in Yemen (4-20%, 1.5% respectively) 
8
. The differences in the 
prevalence between our study and previous studies in Yemen may be attributed to 
differences in the sensitivities of the assays used, the criteria of positivity, types of 
donors as well as in the degree to which individuals with risk factors for blood-borne 
viral infections may have been excluded. In most of the earlier studies, an earlier 
generation of anti-HCV ELISA (which was less sensitive and less specific) was used. 
However, in our study a fourth generation ELISA was used for confirmation, which 
was more sensitive and more specific. 
   In general, the prevalence of hepatitis B and C were lower among young donors than 
older donors in the current study. This confirm the results reported earlier by other 
investigators 
9,10
 this may be explained on the basis of increased exposure with age and 
on the fact that a high awareness of blood-borne viral infections has developed and a 
comprehensive vaccination program against hepatitis B has been implemented in 
Yemen. It should be noted that the carrier rate of HBV was higher than the carrier rate 
of HCV in this study and in other studies 
8-12
.  These data suggested that the mode of 
transmission and the efficiency of transmission of HBV may be different from that of 
HCV. Also, the prevalence of HCV among Yemeni donors was shown to be relatively 
low (0.19%), this was in an agreement with other studies carried in USA (0.29%) 
13
, 
Central America (0.19%) 
14
, Germany (0.1%)
15
, Australia (0.29%)
16
, Singapore 
(0.37%)
17
 and Iran (0.09%) 
18
. This can be explained by an introduction of newer 
generation of anti-HCV testing in BT service has contributed to control and reduction 
of transmission of HCV as this virus is primarily parenterally transmitted. 
Human immunodeficiency virus infection is a major health problem in sub-Saharan 
Africa where the prevalence of HIV among blood donors ranges between 2-20% in 
Kenya
19
 and 5.9% in Ethiopia 
20
. However, our results showed low level of un-
confirmed HIV in the analyzed donors (0.38%). Thus, in our study the prevalence of 
  
HIV in Yemen was recorded as 0.1% among blood donors and other studies have 
reported the lower than our results
21
 this can be explained on the basis that Yemen is an 
Islamic country where religious culture and traditions are practiced, as Islamic rules 
prohibit extramarital sexual activities and drug abuse, in addition to screening of 
expatriates workers entering the Yemen and increased educational awareness have 
contributed to the success of HIV control in Yemen.  
  Conclusion 
In conclusion, this study has shown that prevalence of hepatitis B and C (0.74% and 
0.19%) has reduced in Yemen. Further educational programs should target both public 
and hospital personnel to increase awareness concerning these pathogens. It should be 
noted that the prevalence of hepatitis B and hepatitis C markers was lower among 
young donors than among older donors, hence, young people should be encouraged to 
donate blood to help ensure a long-term increase in the blood supply without 
jeopardizing safety. Finally, implementation of more sensitive tests (such as nucleic 
acid amplification testing [NAT] for HIV, HBV and HCV) that detect infection earlier 
(reduce the window period) will further decrease risks of transfusion-transmitted viral 
infections. Also, further study can be carried out performing NAT on sero-negative 
blood donor samples to determine the risk of transfusion-transmitted. 
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Table 1: The prevalence of HBV, HCV, HIV and T.pallidium among blood donors attending to National 
Blood Transfusion and Research Center during 3 year periods (2016,2017,2018), in Hodeidah city-
Yemen 
Infections Years 
Total 
tested 
Positive 
Total of 3 years 
positive 
No % No % 
HBV 
2016 10817 113 1.04 189 0.74 
2017 10063 50 0.5 
2018 4600 26 0.57 
HCV 
2016 10817 12 0.11 
49 0.19 
2017 10063 18 0.18 
2018 4600 19 0.41 
HIV 
2016 10817 56 0.52 
98 0.38 
2017 10063 27 0.27 
2018 4600 15 0.33 
T.pallidium 
2016 10817 38 0.35 
45 0.18 
2017 10063 5 0.05 
2018 4600 2 0.04 
Co-infection 
2016 10817 2 0.02 
5 0.02 
2017 10063 1 0.01 
2018 4600 2 0.04 
Total 
2016-
2018 
25446 386 1.52 
 
386 
1.52 
Table 2: The prevalence and associated odds ratio of HBV for different age groups for blood donors 
under study in Hodeidah city-Yemen 
Age groups 
Number 
tested 
HBV positive  
OR CI   χ 2     p 
No. % 
17-26 years 11393 86 0.76 1 0.7-1.3 0.04 0.82 
27-36 years 10657 54 0.5 0.5 0.4-0.7 13.7 <0.001 
37-46 years 3052 44 1.44 2.3 1.6-3.1 23 <0.001 
47-56 years 257 5 1.94 2.7 1.1-6.6 5.1 0.02 
  
>56 years 87 0 0 undefined 5.1 0.02 
Total 25446 189 0.74     
OR          Odds ratio = Relative risk, CI           Confidence intervals  
 χ 2          Chi-square = 3.9  or more significant 
 pv           Probability value = 0.05 or less  significant 
 
 
 
 
  
Table 3: The prevalence of HCV and associated odds ratio for different age groups for blood donors 
under stady in Hodeidah city-Yemen. 
Age groups 
Number tested HCV positive  
OR CI   χ 2     p 
 No. % 
17-26 years 11393 27 0.23 1.5 0.8-2.6 2.1 0.14 
27-36 years 10657 15 0.14 0.1 0.3-1.1 2.5 0.1 
37-46 years 3052 4 0.13 0.6 0.2-1.8 0.6 0.41 
47-56 years 257 3 1.2 6.5 1.9-20.9 12.8 0.003 
>56 years 87 0 0 undefined 0.6 0.40 
Total 25446 49 0.19     
 
OR          Odds ratio = Relative risk  
CI           Confidence intervals  
 χ 2          Chi-square = 3.9  or more significant 
 pv           Probability value = 0.05 or less  significant 
 
 
Table 4: The prevalence of HIV and associated odds ratio for different age groups for blood donors 
attending to National Blood Transfusion and Research Center during 3 year periods in Hodeidah city-
Yemen. 
Age groups 
Number tested HIV positive  
OR CI   χ 2     p 
No. % 
17-26 years 11393 47 0.41 1.1 0.7-1.6 0.4 0.51 
27-36 years 10657 35 0.32 0.7 0.5-1.1 1.7 0.19 
37-46 years 3052 16 0.52 1.4 0.83-2.4 1.7 0.18 
47-56 years 257 0 0 undefined 
>56 years 87 0 0 Undefined 
Total 25446 98 0.38     
 
OR          Odds ratio = Relative risk  
CI           Confidence intervals  
 χ 2          Chi-square = 3.9  or more significant 
 pv           Probability value = 0.05 or less  significant 
 
 
  
Table 5: The prevalence of T.pallidium ,  and associated odds ratio for different age groups for blood 
donors under study in Hodeidah city-Yemen. 
Age groups 
Number tested T.pallidium 
positive  
OR CI   χ 2     p 
No. % 
17-26 years 11393 10 0.088 0.3 0.17-0.7 9.2 <0.001 
27-36 years 10657 19 0.18 1.1 0.5-1.8 0.002 0.95 
37-46 years 3052 15 0.49 3.6 1.9-6.8 19.4 <0.001 
47-56 years 257 1 0.39 2.2 0.3-16.2 0.6 0.41 
>56 years 87 0 0 undefined 
Total 25446 45 0.18     
OR          Odds ratio = Relative risk  
CI           Confidence intervals  
 χ 2          Chi-square = 3.9  or more significant 
 pv           Probability value = 0.05 or less  significant 
   
